Moreover, many results are contradictory with other studies, as illustrated with miRNAs (e.g., miR-21, associated with a poor prognosis in SMZL, but with a good prognosis in DLCBL), or specific genetic mutations (e.g., BIRC3 inactivation associated with poor prognosis in chronic lymphocytic leukemia [69], which is the contrary in other solid tumors or hematologic malignancies [70]). Here, BIRC3 is linked to hematologic disorder.